Immune Response News and Research

RSS

Tracking genes in infant's intestine helps compare early development of breast-fed and formula-fed babies

Is breast milk so different from infant formula? The ability to track which genes are operating in an infant's intestine has allowed University of Illinois scientists to compare the early development of breast-fed and formula-fed babies. They say the difference is very real.

13 May 2010

Giardia's surface proteins may work as vaccines to help prevent infections: Research scholar

The intestinal parasite Giardia lamblia changes outfits nearly as often as a fashion model on a Parisian runway. With more than 200 protein coats in its molecular wardrobe, this troublesome creature-the cause of innumerable cases of diarrheal infections each year-can change its appearance from one instant to the next, throwing the body's immune cells off track.

12 May 2010

Potential new drug therapies for treatment of tuberculosis

Tuberculosis (TB) has been present in humans since ancient times. The origins of the disease date back to the first domestication of cattle, and skeletal remains show prehistoric humans (4,000 B.C.) had TB. Although relatively rare in the United States, it is the single leading bacterial cause of death worldwide. Approximately 8 million people are infected each year and 2 million people die from TB.

11 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

Protein PEA-15 stops T-cell proliferation

New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.

5 May 2010

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Immune system responds aggressively when looking at sick people

Just seeing someone who looks sick is enough to make your immune system work harder, according to a new study in which volunteers looked at pictures of sick people. This may help fight off pathogens, says Mark Schaller from the University of British Columbia who conducted the research. "It seems like it's probably good for the immune system to be responding especially aggressively at times when it looks like you are likely to be coming into contact with something that might make you sick."

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

3 May 2010

Leptin hormone controls immune’s response to sepsis: Study

The hormone leptin, typically associated with body weight regulation, works within the central nervous system (CNS) to aid the immune system's defense against sepsis, researchers say.

3 May 2010

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Current research suggests that tumor-secreted exosomes inhibit the immune response, enhancing tumor metastasis. The related report by Liu et al, "Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells," appears in the May 2010 issue of The American Journal of Pathology.

3 May 2010

Liver transplant recipients develop premature immune senescence: Researchers

Researchers at the University of Cambridge found that liver transplant recipients develop premature immune senescence, the normal process by which the immune system ages and becomes less effective. Full details appear in the May issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

30 Apr 2010

Short-term calorie restriction improves function of T-cells

Scientists funded by the Agricultural Research Service (ARS) found that volunteers who followed a low-calorie diet or a very low-calorie diet not only lost weight, but also significantly enhanced their immune response. The study may be the first to demonstrate the interaction between calorie restriction and immune markers among humans.

30 Apr 2010

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

New tool to detect inflammatory eye disease at molecular level before damage occurs

Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

Immune Response News and Research

Tracking genes in infant's intestine helps compare early development of breast-fed and formula-fed babies

Giardia's surface proteins may work as vaccines to help prevent infections: Research scholar

Potential new drug therapies for treatment of tuberculosis

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

Protein PEA-15 stops T-cell proliferation

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Immune system responds aggressively when looking at sick people

Novel combined immunotherapy promising for treatment of malignant brain tumors

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Leptin hormone controls immune’s response to sepsis: Study

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Liver transplant recipients develop premature immune senescence: Researchers

Short-term calorie restriction improves function of T-cells

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

New tool to detect inflammatory eye disease at molecular level before damage occurs

PROVENGE receives FDA approval for treatment of CRPC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News